Dr Malcolm Boyce

Dr Malcolm Boyce

Medical and Managing Director of Hammersmith Medicines Research Ltd

I’m the Medical and Managing Director of Hammersmith Medicines Research Ltd (HMR), a contract research organisation that specialises in the first clinical trials of potential new medicines for pharmaceutical and biotechnology companies worldwide. I’ve been the principal investigator or co-investigator for over 700 of such trials. HMR has its own facilities in NW London with 145 beds, an on-site pharmacy and laboratory, and employs 240 people, including physicians, nurses, pharmacists and support staff.
I qualified in physiology and medicine in Bristol.  I’m a Fellow of the Royal College of Physicians, the Faculty of Pharmaceutical Medicine, and the British Pharmacological Society, and an Honorary Senior Lecturer in Clinical Pharmacology at St Bartholomew’s Hospital Medical College, London.
I’ve held various posts in clinical and academic medicine, and I’ve worked for several of the major pharmaceutical companies, during which time I carried out or coordinated numerous clinical trials in Europe and the USA across all phases of drug development with a wide variety of new medicines.
I’m chairman of the Faculty of Pharmaceutical Medicine Diploma in Human Pharmacology/Certificate in Human Pharmacology Advisory Committee, and a member of MHRA GCP Consultative Committee and the National Research Ethics Advisory Panel, and a former member of the London Research Ethics Committee. 
I’ve published many articles in journals and books on clinical trials, drug development and research ethics.
HMR has a subsidiary company, Trio Medicines Ltd (Trio), that researches and develops its own potential new medicines. One of those, called ceclazepide, blocks the effects of gastrin, a hormone that circulates in the bloodstream of all people, but at much higher amounts in people with pernicious anaemia (PA). In some patients with PA, too much gastrin causes growth of cells, called ECL cells, in the stomach lining to form tumours, called gastric neuroendocrine tumours (g-NETs for short). g-NETs are mostly harmless, but they can become harmful and spread in some people. Ideally, people with PA should have regular gastroscopy (looking into the stomach with a thin, flexible instrument with a light at the end) to check for g-NETs. Sometimes the tumours need removing surgically. However, a recent survey in members of the PA Society (PAS) showed that not many of them have regular gastroscopy. Ceclazepide offers a novel medical treatment of g-NETs in people with PA as an alternative to surgery. Trio has already shown that a gastrin blocker related to ceclazepide can eradicate g-NETs in people with PA. Trio would like members of the PAS to volunteer for clinical trials of ceclazepide, which should start early 2017.

Pin It on Pinterest

Share This